Shares of Abbott Laboratories (NYSE:ABT) lost ~5% in the premarket on Thursday after the MedTech company provided its ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) beat Wall Street’s revenue expectations in Q2 CY2025, ...

Abbott stock toppled early Thursday after the health giant issued a light organic sales outlook for 2025, though it beat ...

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) will be announcing earnings results this Thursday ...

Abbott Laboratories stock falls after earnings even as the company reports second-quarter sales that top expectations.

Abbott Laboratories (NYSE: ABT) is scheduled to announce Q2 earnings results on Thursday, July 17th, before market open.

For the current quarter ending in September, Abbott expects its per-share earnings to range from $1.28 to $1.32. The company ...

Barclays analyst Matt Miksic maintained an Overweight rating and increased the price target from $158 to $159 on April 17, ...

Abbott Laboratories (NYSE: ABT) is one of the stocks that Jim Cramer shared insights on. While discussing the stock, Cramer ...

Abbott Laboratories closed 6.52% below its 52-week high of $141.23, which the company reached on March 4th.

Abbott Laboratories received FDA approval for its Amulet device to treat people with atrial fibrillation who are at risk of ischemic stroke. The device would go head-to-head with one developed by ...